Prostate cancer is the second most common cancer and the leading cause of cancer-related death in men worldwide. Continuous androgen deprivation therapy (ADT) is recommended as first-line treatment for metastatic and hormone-naive disease. These patients eventually gain resistance to ADT. The level of PSA of patients increase, the levels of testosterone areat castration, and the disease progress in a few years. Currently, chemotherapy (CT) is often recommended in combination with ADT as the initial treatment for metastatic prostate cancer castre-resistance prostate cancer (mCRPC) with high tumor volume.1